ChristianaCare offers monoclonal antibody treatment (mAb), Bebtelovimab, to help those at high risk of complications from COVID-19.
Your body naturally makes antibodies to fight infection. However, your body may not have antibodies designed to recognize a new virus like the one that causes COVID-19. Monoclonal antibodies are made in a laboratory to fight a particular infection based on natural antibodies against COVID-19. The mAb treatment can help patients who are at high risk for severe symptoms or hospitalization from COVID-19. In addition, they can help shorten the course of illness from COVID-19 and prevent hospitalization.
Monoclonal antibodies are not a cure for COVID-19.
Monoclonal antibodies are made in the lab to help your body fight COVID-19. They are not a cure, but they may help keep your symptoms from becoming more serious and they may help shorten the amount of time you are sick from COVID-19. This therapy is authorized for emergency use only by the U.S. Food and Drug Administration (FDA) but it hasn’t been approved yet.
This medication is currently being provided at our specialty infusion center at ChristianaCare’s Newark campus. You can not get this therapy in the emergency department, in clinics or if you are already in the hospital with COVID-19. If your provider is within ChristianaCare, they can place a referral to activate the process. If your provider is not within ChristianaCare or you would like to make a self-referral as a patient, then please call 302-428-2121 and select provider option 1 for referrals.